The latest

News

Latest news164

Audience in the Bakar Bio Labs auditorium

Lunch & Learn with Levitree and Equator Therapeutics

On Wednesday, at our first our first Lunch and Learn for 2025, the founders of Levitree and Equator Therapeutics came to present their work and their teams, giving the greater Bakar Bio Labs community a better sense of what they do. Read post
The Futurebio team in the lab

Is a New Type of Plastic a Solution to the Climate Crisis? FutureBio, First Tenant in Bakar Climate Labs Pilot Program, Says Yes.

FutureBio is the first tenant in the pilot program at UC Berkeley’s new climate tech incubator: Bakar Climate Labs. Until the new incubator on the west side of campus opens in 2028, the pilot program is accepting startups leasing space at Bakar Bio Labs and the QB3 Garage incubator in Stanley Hall. But FutureBio isn’t waiting for the ink to dry on blueprints—they’re already moving forward, transforming the way we think about plastic and our planet’s future. Read post

We Are Now Bakar Bio Labs

We have a new name! And logo. As the larger Bakar Labs organization expands into multiple locations and adds the climate tech vertical, our goal is to keep our branding as clear as possible. So we are now Bakar Bio Labs, as you probably noticed. Going forward, the general “Bakar Labs” title will be reserved for the parent organization we fall under. Beneath the Bakar Labs umbrella there are two units: Bakar Bio Labs and Bakar Climate Labs, for which our pilot program is now live (the facility, on the west side of the UC Berkeley campus, will open in 2028). Bakar Bio Labs will operate at two locations: the original, at 2630 Bancroft Way in Berkeley, and a new UCSF building in development in the Dogpatch neighborhood in San Francisco. Read post
Marco Lobba, Rachel Haurwitz, and Wei Wu

Event Recap: “Working With Strategic Investors”

“Between all these investors and companies,” Haurwitz said, “I think it becomes very clear over time that different incentives drive different interactions.” She advises building personal relationships to find out how and why each fund makes investments: some for profit, some for strategic reasons (like licensing or later acquisition); sometimes both at the same fund. (Haurwitz was the first student to work on CRISPR in Jennifer Doudna’s lab, she said; traditional VCs had no interest in CRISPR while CVCs – Dupont first among them – were knocking on the door, quick to see the long-term potential.) Read post

At Biotech’s Biggest Conference, UC Berkeley Shows Off Startups

In a way, biotech startup Editpep’s story is one faced by many new life sciences companies in a tough funding environment; in a way, too, it is so Berkeley. Co-founded by University of California, Berkeley postdoctoral researcher looking at ways to cure genetic diseases, an MBA student and a scientific disciple of CRISPR gene-editing technology pioneer Jennifer Doudna, Editpep last month secured an $8.4 million seed financing to take on pediatric brain cancer and other brain diseases. Read post
sophia lugo

‘You have to believe that you can be a leader’: Sophia Lugo, NHI’s 2024 Person of the Year

Sophia Lugo has made a remarkable journey in her career so far, moving from Silva Magnet/Jefferson High School in El Paso to Harvard University for undergraduate studies on biology, the Schwarzman Scholars program at Tsinghua University for graduate studies in public policy, and Stanford University for her MBA, work with entities including the Boston Consulting Group and the Bill & Melinda Gates Foundation, eventually becoming co-founder and CEO of a company aiming to change medicine as we know it. Read post
incubator

What to Look for in a Biotech Incubator

Gino Segre, managing director of Bakar Labs, confirms that there is plenty you can look at to see if an incubator is successful. “Tenant occupancy relative to other incubators, fundraising success of the tenants over time, and word of mouth satisfaction are good indicators of the operating track record of the incubator.” Reaching out to former incubees to have direct feedback on their experience with the incubator is one of your strongest indicators if this is the right direction for you. Read post
Depiction of atherosclerosis

Cyclarity Therapeutics Secures Approval for First-in-Human Clinical Trial

Cyclarity Therapeutics is pleased to announce regulatory approval to begin its first-in-human clinical trial. The trial will be conducted at CMAX, one of Australia’s leading clinical research centers, in partnership with Monash University. This effort will be led by Dr. Stephen Nicholls of the Victorian Heart Institute (VHI), a distinguished leader in cardiovascular medicine. In addition to a traditional SAD/MAD phase 1 trial, the authorization includes an allowance to enroll 12 patients with Acute Coronary Syndrome (ACS) to assess the safety of UDP-003 in individuals with plaque buildup, as well as to explore anecdotal evidence of efficacy. This represents a critical first step in evaluating the potential impact of our therapy in a population with high unmet need. Read post
Clockwise from top left: Shakked Halperin, Tim Craven, the Profluent team, the Radar team, members of HOPO Therapeutics

Looking Forward to 2025 from Our Top Five Stories of 2024

Happy new year! At Bakar Labs we’re looking forward to a great 2025, starting of course with the JP Morgan Healthcare Conference in SF. Other highlights in the near future: the return of our JETRO entrepreneurs from Japan; the rollout of the Bakar Climate Labs pilot program (look for our web story on Futurebio, our first climate tech tenant); if you’re at the BIO International Convention in Boston, look for our team, we’ll be there. You can count on our September Showcase and our November anniversary party to be bangers. Community is our #1 asset. Thank you for being part of it! Read post

Startup ResVita Bio Targets Rare, Deadly Skin Disease With a Bacterial Factory

Amin Zargar literally put skin in his scientific game. Now he hopes to add a deeper layer of funding to his East Bay startup to boost its work on a treatment for a rare and deadly skin disease. Zargar as a postdoctoral fellow was on an academic track and looking for a job as he stress-tested an idea kicked around with mentor Jay Keasling, a pioneer in synthetic biology at UC Berkeley. What if, they thought, they could genetically engineer a bacteria to convert sugars in skin lotions into therapeutic proteins continuously pumped onto the skin's surface? In essence, the bacteria would become a 24/7 factory for producing healing proteins. Read post
ariz logo

ARIZ and NATA Announce Collaboration to develop multiple targeted nucleic acid therapies for cancer treatment

ARIZ and NATA have announced an exciting new partnership aimed at advancing cancer treatment through the development of multiple targeted nucleic acid therapies. By combining ARIZ’s cutting-edge research and NATA’s expertise in molecular medicine, the collaboration seeks to pave the way for innovative therapies that could revolutionize the way cancer is treated. This strategic alliance marks a significant step forward in the fight against cancer, offering new hope for more personalized and effective treatments. Read post
brad niles

Tenant Spotlight on ARIZ: Rising to the Challenge to Make Cancer Treatments More Humane 

Cancer treatments are often as grueling as the disease itself—chemotherapy can bring unbearable side effects like debilitating fatigue, nausea, and hair loss, leaving patients vulnerable and stripped of their identity. But what if cancer care could be better? More precise? Less harmful? Enter ARIZ Precision Medicine. Their mission is to revolutionize cancer care by developing therapies that not only fight the disease but also preserve the quality of life for patients. Learn how they're doing this in our latest Tenant Spotlight. Read post